RP-UFLC Method Development and Validation of Rifaximin in Bulk and Tablet Dosage Form

International Journal of Pharmacy and Biomedical Engineering

© 2019 by SSRG - IJPBE Journal

Volume 6 Issue 1

Year of Publication : 2019

Authors : Srinidhi B. S, Jose Gnana Babu C and Senthil Kumar G. P

10.14445/23942576/IJPBE-V6I1P105

How to Cite?

Srinidhi B. S, Jose Gnana Babu C and Senthil Kumar G. P, "RP-UFLC Method Development and Validation of Rifaximin in Bulk and Tablet Dosage Form," SSRG International Journal of Pharmacy and Biomedical Engineering, vol. 6,  no. 1, pp. 35-39, 2019. Crossref, https://doi.org/10.14445/23942576/IJPBE-V6I1P105

Abstract:

A simple, novel, accurate, precise, linear, rapid, and economic RP-UFLC method was developed for the estimation of Rifaximin in bulk and tablet dosage form. The chromatographic separation was achieved using a PhenomenexLuna C18 (250 x 4.6 mm, 5 μ) column and binary gradient elution, a mobile phase comprising of Methanol: Water in the ratio (95:5). The flow rate was 1.0ml/min with detection at 235nm using a UV detector and drug eluted with a retention time of 3.44 min. The calibration curves were linear (r²=0.999) in the concentration range of 2-10 μg/ml. The limit of detection and limit of quantitation were found to be 2.5148195 and 7.6206642 μg/ml, respectively. The developed method was validated as per ICH guidelines. Hence it is successfully applied for the quantitative estimation of Rifaximin in tablet dosage form.

Keywords:

- Rifaximin, ICH guidelines, RP-UFLC

References:

[1] https://www.drugbank.ca>drugs.
[2] https://en.wikipedia.org/wiki/Rifaximin.
[3] T.Sudha, P. V Hemalatha, V.R Ravikumar. Development and validation of the rp-hplc method for the estimation of rifaximin in bulk and in the tablet dosage form. Asian Journal of Pharmaceutical and Clinical Research. 2(1);85- 89:2012.
[4] S. Sumakala, S. Vijayaraj, and N. R Dharani. Development and validation of stability are indicating the rp-hplc method for the estimation of rifaximin in bulk and formulation. International Journal of Advanced Research. 4(9);200- 207:2016.
[5] M. Mathrusri Annapurna, B. Sai Pavan Kumar, B. Venkatesh, Development and Validation of a Stability-Indicating HighPerformance Liquid Chromatographic Assay for Rifaximin in Bulk and Pharmaceutical Dosage Forms. Drug Invention Today. 4(8);430-434:2012.
[6] B. R. Challa, M. R. Kotaiah, B. R. Chandu et al., HPLC Method for Determination of Rifaximin in Human Plasma Using Tandem Mass Spectrometry Detection. East and Central African Journal of Pharmaceutical Sciences. 1(3);78- 84:2010.
[7] BikshalBabuKasimala, Reshma Syed, KalpanaPammi. Rphplc method development and validation for the analysis of rifaximin in pharmaceutical dosage forms. International journal of research and reviews in pharmacy and applied sciences. 1(4);323-333:2011.
[8] M. Mathrusriannapurna, B. SaiPavan Kumar, and B. Venkatesh. Development and Validation of StabilityIndicating Liquid Chromatographic Assay for Rifaximin in Bulk and Pharmaceutical Dosage Forms. Chemical Science Transactions. 3(2);566-575:2014.
[9] K. NageswaraRao, S. Ganapaty, and A. Lakshmana Rao. Rphplc determination of rifaximin in bulk drug and pharmaceutical formulations. International Journal of pharmacy. 3(1);7-13:2013.
[10] A. Narendra, M. Mathrusriannapurnab, k. Ravi Kumar. Development and validation of the stability-indicating liquid chromatographic method for Rifaximin an antibiotic. Journal of Drug Delivery & Therapeutics. 3(1);18-25:2013.
[11] AbidFidaMasih. Forced degradation study of Rifaximin formulated tablets to determine the stability-indicating nature of the Hplc method. International Journal of Chemical and Pharmaceutical Analysis. 4(3);1-10:2017.
[12] Dinesh Reddy Salla and VidhyakiniDhanthala. A Validated RP-HPLC Method for Estimation of Rifaximin in its Bulk and Pharmaceutical Dosage Forms. International Journal for Pharmaceutical Research Scholars. 4(1);11-20:2017.
[13] P.G.Sunitha, S.Hemalatha, and K. Rama. Development and Validation of Stability Indicating RP-HPLC (PDA) Method for Estimation of Rifaximin and Ornidazole in Bulk and Combined Tablet Dosage Formulation. International Journal of Chem Tech Research. 11(5);85-95:2018.
[14] ICH, Q2A Text on Validation of Analytical Procedures; 1994.
[15] ICH, Q2B Validation of Analytical Methodology; 1996.
[16] ICH, Q2 (R1) Validation of Analytical Procedures: Text and methodology; 2005.